CIVILICA We Respect the Science
(ناشر تخصصی کنفرانسهای کشور / شماره مجوز انتشارات از وزارت فرهنگ و ارشاد اسلامی: ۸۹۷۱)

BENEFITS OF CURCUMIN SUPPLEMENTATION ON ANTIOXIDANT STATUS IN Β-THALASSEMIA MAJOR PATIENTS: A DOUBLE-BLIND RANDOMIZED CONTROLLED CLINICAL TRIAL

عنوان مقاله: BENEFITS OF CURCUMIN SUPPLEMENTATION ON ANTIOXIDANT STATUS IN Β-THALASSEMIA MAJOR PATIENTS: A DOUBLE-BLIND RANDOMIZED CONTROLLED CLINICAL TRIAL
شناسه ملی مقاله: INC15_361
منتشر شده در سومین کنگره بین المللی و پانزدهمین کنگره تغذیه ایران در سال 1397
مشخصات نویسندگان مقاله:

Elahe Mohammadi - National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Esmat Nasseri - National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Durdi Qujeq - Cellular and Molecular Biology Research Center, Health Research Institute, Faculty of Medicine, Babol University of Medical Sciences, Babol
Ahmad Tamaddoni - Non-Communicable Pediatric Diseases Research Center, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran

خلاصه مقاله:
Background and Aim: β-Thalassemia major is the most common inherited anemia in the world (1). Regular blood transfusion therapy in these patients leads to iron overload, oxidative stress and tissue damage (1). Based on previous studies curcumin, the active polyphenol in turmeric has significant therapeutic potential such as anti-cancer, iron binding and antioxidant activities (2-4). The objective of this study was to evaluate the efficacy of curcumin supplementation on markers of oxidative stress in patients with β-Thalassemia major.Methods: 68 Male and female patients with β-thalassemia major between 18 and 40 years old were eligible for inclusion in this double-blind randomized controlled clinical trial if they were on stable medication with deferoxamine and regular transfusion program. The study exclusion criteria included: changes in drug regimen during the study, taking any nutritional supplements, having a history of hepatitis B, C and HIV infection, pregnancy and lactation. The registration ID of this study in Iranian Registry of Clinical Trials was: IRCT2016053028165N1. The patients were randomly allocated in two groups using a randomized block design via the random allocation software (RAS), with subjects matched in each block by sex and age. Subjects in the curcumin group (n=34) received two 500 mg curcumin capsules daily and patients in the placebo group (n=34) administered 2 placebo capsules daily for 12 weeks. Dietary intakes and biochemical parameters including Hb, serum iron, ferritin, malondialdehyde (MDA), total antioxidant capacity (TAC), catalase and vitamin E were assessed at the beginning and the end of intervention. Statistical analysis was performed using SPSS software (version 17).Results: 61 patients completed the trial. No significant differences in biochemical variables, energy, macro and micronutrients were observed between two groups at baseline. The mean dietary intake of vitamin E decreased in curcumin group at the end of the study in comparison with baseline (11.51±7.40 vs 9.84±6.06 mg/day, p=0.046). At the end of the study, serum MDA significantly decreased (41.03±14.96 vs 37.12±11.70 µmol/L, p=0.002) and TAC significantly increased (187.09±82.26 vs 207.96±91.72 µmol/L, p= 0.005) in the curcumin group. A considerable fall in ferritin level was observed in curcumin group during the study period; nevertheless did not attain statistical significance (1612.54± 502.36 vs 1538.09 ± 439.81 ng/ml, p=0.059).Based on the analysis of covariance, a significant reduction in MDA was also detected in the curcumin group when compared to the placebo group (37.12±11.70 vs 39.90±12.37 µmol/L, p=0.001) adjusted for baseline values and dietary intakes of iron and vitamin E. Levels of Hb, iron, ferritin, TAC, catalase and vitamin E remained unchanged between two groups after treatment.Conclusion: As a conclusion curcumin supplementation in combination with deferoxamin improved the antioxidant status in β-thalassemia major patients. Curcumin may alleviates oxidative stress via several mechanisms including radical scavenging by the β-diketone moiety in curcumin structure, upregulating antioxidant enzymes by triggering some nuclear factors and moreover by its iron binding activity (5-7). Curcumin may be useful for the relief of some metabolic complications in these patients.

کلمات کلیدی:
β-thalassemia major; Curcumin; Antioxidant status; Randomized clinical trial

صفحه اختصاصی مقاله و دریافت فایل کامل: https://civilica.com/doc/816395/